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Which is the Better Prognostic Factor for Resected
Non-small Cell Lung Cancer
The Number of Metastatic Lymph Nodes or the Currently Used
Nodal Stage Classification?
Shenhai Wei, MD, PhD,*† Hisao Asamura, MD,* Riken Kawachi, MD,* Hiroyuki Sakurai, MD,*
and Shun-ichi Watanabe, MD*
Introduction: This retrospective study was conducted to evaluate
the prognostic significance of the number of metastatic lymph nodes
(nN) in resected non-small cell lung cancer (NSCLC) in comparison
with the currently used pathologic nodal (pN) category in the staging
system.
Methods: A total of 1659 patients who underwent potentially
curative resection for NSCLC from 2000 to 2006 were included in
this study. The association between the nN and survival was ex-
plored, and the results were compared with those using the location-
based pN stage classification.
Results: The patients were divided into four categories according to
the number of metastatic nodes: nN0, absence of metastatic nodes;
nN1, metastasis in one to two nodes; nN2, metastasis in three to six
nodes; and nN3, metastasis in seven or more nodes. The 5-year
overall survival for nN0, nN1, nN2, and nN3 was 89.2%, 65.1%,
42.1%, and 22.4%, respectively (p 0.001). The nN category could
be used to subdivide pN1 and pN2 patients into two (nN1 and nN2)
and three (nN1, nN2, and nN3) prognostically distinct subgroups,
respectively. Multivariate analysis showed the nN category was an
independent prognostic factor for resected NSCLC. The difference
in overall survival between pN1 and pN2 was not significant (55.4%
versus 47.8%, p 0.245). Patients in each nN category could not be
subdivided into different prognostic subgroups according to the pN
classification.
Conclusions: The nN category in this study was shown to be a
better prognostic determinant than the location-based pN stage
classification.
Key Words: Non-small cell lung cancer, Lymph node metastasis,
Prognosis.
(J Thorac Oncol. 2011;6: 310–318)
The accurate assessment of lymph node involvement iscrucial for the diagnosis and treatment of non-small cell
lung cancer (NSCLC). Recently, the seventh edition of the
tumor-node-metastasis (TNM) classification for NSCLC has
been accepted with some modifications in comparison with
the sixth edition.1 However, the node (N) descriptor in the
new classification remains the same as in the previous edition
and depends solely on the anatomic extent of lymph node
involvement despite the change in the nodal map.
Patients suffering from pathologic N1 or N2 disease in
NSCLC have long been known to exhibit prognostic hetero-
geneity.2–13 This has indicated that it is necessary to refine the
currently used pathologic N (pN) stage classification and has
justified attempts to identify alternative nodal classification
methods. In some other solid tumors, such as breast, gastric,
and colorectal cancer, the number of metastatic lymph nodes
has been considered in the TNM staging system.14 Recently,
the number of metastatic lymph nodes (nN), when classified
into several categories, has been shown to be a prognostic
factor for resected NSCLC.9,15 However, to date, it is still
unknown whether the nN category or the pN stage classifi-
cation is the better prognostic factor. In this study, we
retrospectively evaluated the association between the nN
category and the prognosis of resected NSCLC and compared
the results with the classic pN stage classification.
PATIENTS AND METHODS
Patient Selection
A total of 2333 consecutive patients with NSCLC who
underwent surgery at the National Cancer Center Hospital,
Tokyo, from January 2000 to December 2006 were examined
retrospectively. The Institutional Review Board approved this
retrospective study, and informed consent from patients was
waived.
All the patients received a thorough work-up preoper-
atively, including computed tomography (CT) scan, chest
radiograph, blood test, and positron emission tomography
(PET), if necessary, to evaluate their eligibility for surgery.
Patients who were identified to have distant metastasis or
clinical N2 (cN2) diseases preoperatively were excluded from
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surgery. Clinical N2 disease was suspected when mediastinal
lymph node enlargement was present with a minimal diam-
eter of 1.0 cm or more on the CT scan. If the following PET
scan or mediastinoscopy was positive, we considered it as
cN2 disease and excluded from surgery. PET scan and me-
diastinoscopy were used only for suspected cN2 disease
rather than for all patients.
Patients with a prior history of malignant disease or
induction therapy before surgery and those who underwent
explorative thoracotomy were not included in this study. In
addition, those who died within 30 days after surgery, those
for whom no lymph node was retrieved or no such data were
available, and those for whom follow-up information was
unavailable were also excluded. Ultimately, a total of 1659
patients were included in this study (Figure 1).
Procedure Performed
Procedures performed for the affected pulmonary con-
sisted of wedge resection/segmentectomy, lobectomy, bilo-
bectomy, and pneumonectomy. Wedge resection or segmen-
tectomy was performed only for the high-risk patients,
combined with minimal lymph node dissection, sometimes
maybe around the hilum only. For all the other patients, we
performed lymph node dissection based on the lobe-specific
patterns of nodal metastases.16,17 When the cancer located in
right upper lobe or left upper division, the hilar lymph nodes
and upper mediastinal lymph nodes were dissected. The
upper mediastinal lymph nodes indicate highest mediastinal
nodes, paratracheal nodes, pretracheal nodes, and tracheo-
bronchial nodes in right side and aortopulmonary window
nodes, paraaortic nodes, and tracheobronchial nodes in left
side. If intraoperative frozen section of the lymph node in
either hilum or upper mediastinum was positive, we per-
formed subcarinal dissection, which was omitted otherwise.
For the tumor located in right middle lobe or left lingular
segment, the lymph nodes in both upper mediastinum and
subcarina were routinely dissected in addition to the hilum.
When the tumor located in lower lobe, the hilar and lower
mediastinal lymph nodes (including stations 7, 8, and 9) were
dissected. If intraoperative pathologic examination of either
the hilar or the lower mediastinal lymph node was positive,
we performed additionally upper mediastinum dissection,
which was omitted otherwise.
Data Collected and Statistical Analyses
The data collected included the patient demograph-
ics, surgical procedures, and pathologic reports including
the histologic type, T stage, and the number and location of
all the malignant and benign lymph nodes. The TNM
classification was based on the sixth edition of the TNM
staging system.18
We choose overall survival (OS) and disease-free sur-
vival (DFS) as the end points. OS was the time between
surgery and death from any cause. DFS was the time from
surgery to locoregional or distant relapse of lung cancer, and
if without relapse, any deaths due to causes other than lung
cancer would be censored. Continuous variables are ex-
pressed as the mean  SD. The associations between vari-
ables were analyzed by either 2 test or Mann-Whitney and
Wilcoxon tests. Survival curves were generated by the
Kaplan-Meier method, and differences in survival among
subgroups were examined by the log-rank test. A multivariate
analysis was performed using Cox proportional hazards mod-
els to examine the association between survival and potential
prognostic factors. A probability value of less than 0.05 was
considered to be significant. All statistical calculations were
performed using SPSS for Windows version 11.5 (SPSS Inc.,
Chicago, IL).
RESULTS
Patient Characteristics
The 1659 patients in this study consisted of 962 men
and 697 women with a mean age of 63.8 10.0 years (range,
26–89 years). The characteristics of the patients are shown
in Table 1. The most frequent procedure performed was
lobectomy (86.4%, n  1434), followed by wedge resec-
tion/segmentectomy (5.4%, n  90). Adenocarcinoma was
found in 78.3% (n  1299) of the patients, and the second
most common histologic type was squamous cell carci-
noma (17.4%, n  288). A positive surgical margin was
confirmed in 95 (5.7%) patients by pathologic examina-
tion. A total of 102 (6.1%) patients were classified as stage
IIIb due to pleural dissemination or separate tumor nod-
ule(s) in the same lobe identified during the operation,
rather than pN3 disease. Stage IV disease (0.4%, n  7)
consisted of separate tumor nodule(s) in a different ipsi-
lateral lobe identified during surgery.
FIGURE 1. Patients included in this study.
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Lymph Node Metastasis and Definition of nN
Category
The mean number of lymph nodes retrieved from each
patient was 15.9 9.5 (range, 1–79). Lymph node metastasis
was seen in 456 patients. The mean number of metastatic
lymph nodes was 4.11  4.43 (range, 1–29). Among the
patients with nodal metastasis, 213 were identified as pN1
and 243 were pN2. The distribution of the number of meta-
static lymph nodes in pN1 and pN2 is shown in Figure 2. The
pN2 stage had more lymph node metastasis than pN1 (5.74
5.35 versus 2.26  1.71, p  0.001) (Table 2).
The last follow-up visit was in August 2007, and the
median follow-up duration was 30.0 months (range, 1–88
months). During the follow-up period, 386 cases suffered
from locoregional or distant recurrence of lung cancer, and
214 cases died due to any cause. The 5-year OS and DFS
rates for the overall population were 78.9% and 68.4%,
respectively.
OS deteriorated with an increase in the number of
metastatic lymph nodes (Figure 3). We classified the patients
into four nN categories, and the survival curves that were
FIGURE 2. Distribution of the metastatic lymph nodes in
pN1 and pN2 stage.
FIGURE 3. The survival curves according to different num-
ber of metastatic lymph nodes.
TABLE 2. Comparison of Number of Metastatic Lymph
Nodes between pN1 and pN2 Stage
pN Stage
Number of Metastatic Lymph
Nodes (Mean  SD) p
pN1 2.26  1.71 0.001
pN2 5.74  5.35
TABLE 1. Patient Characteristics
Patient Characteristics N (%)
Age (range) 63.8  10.0 (26–89)
Gender
Male 962 (58%)
Female 697 (42%)
Surgical procedure
Wedge resection/segmentectomy 90 (5.4%)
Lobectomy 1434 (86.4%)
Bilobectomy 60 (3.6%)
Pneumonectomy 75 (4.5%)
Surgical margin
Positive 95 (5.7%)
Negative 1564 (94.3%)
Histological type
Adenocarcinoma 1299 (78.3%)
Squamous cell carcinoma 288 (17.4%)
Large cell carcinoma 53 (3.2%)
Adenosquamous carcinoma 19 (1.1%)
pT stage
pT1 953 (57.4%)
pT2 500 (30.1%)
pT3 109 (6.6%)
pT4 97 (5.8%)
pN stage
pN0 1203 (72.5%)
pN1 213 (12.8%)
pN2 243 (14.6%)
UICC stage (sixth edition)
Ia 813 (45.0%)
Ib 302 (18.2%)
IIa 65 (3.9%)
IIb 156 (9.4%)
IIIa 214 (12.9%)
IIIb 102 (6.1%)
IV 7 (0.4%)
UICC, International Union Against Cancer.
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close to each other were grouped into a single category.
Finally, the four nN categories were defined as follows: nN0,
no lymph node metastasis; nN1, metastasis in one to two
nodes; nN2, metastasis in three to six nodes; and nN3,
metastasis in seven or more lymph nodes.
Prognostic Significance of nN Category and
Comparison with pN Stage Classification
The OS and DFS in each pN stage classification and nN
category were explored. Patients without lymph node metas-
tasis (pN0 and nN0) had the most favorable prognosis, with
5-year OS and DFS rates of 89.2% and 83.2%, respectively.
There was a significant difference between pN1 and pN2
disease with regard to DFS (5-year DFS rate: 37.3% versus
24.5%, p 0.026), but the difference in OS was not significant
(5-year OS rate: 55.4% versus 47.8%, p  0.245) (Figures 4A,
B). DFS and OS according to the nN category are shown in
Figures 4C, D. The survival curves showed clear differences in
OS and DFS for each of the nN categories (5-year OS rate for
nN0, nN1, nN2, and nN3 was 89.2%, 65.1%, 42.1%, and 22.4%,
respectively, p  0.001; 5-year DFS rate was 83.2%, 44.1%,
23.0%, and 6.5%, respectively, p  0.001).
A validation of the results of the nN category in terms
of OS across each pT stage was performed. The results were
showed in Figure 5. Although the differences between each
pair of nN categories were not always significant, there was
a clear tendency of deterioration of the OS from nN0 to nN3
subgroup, and the curves were apart from each other in pT1
and pT2 patients. There were similar results in terms of DFS
(data not shown).
When pN1 patients were subdivided into nN1, nN2,
and nN3 subgroups, there was a significant difference be-
tween the nN1 and nN2 subgroups with regard to both OS
(5-year OS rate: 61.5% versus 35.6%, p  0.033) and DFS
(5-year DFS rate: 41.6% versus 25.0%, p  0.020). No
significant difference was observed when nN3 was compared
with either the nN1 or nN2 subgroup (p  0.375 and 0.759,
respectively) (Figures 6A, B). The survival curves for OS and
DFS showed distinct differences between the nN categories
when pN2 patients were subdivided into different nN sub-
groups (5-year OS rate for nN1, nN2, and nN3 subgroup was
72.0%, 45.6%, and 19.4%, respectively, p  0.001; 5-year
DFS rate was 48.0%, 23.0%, and 3.9%, respectively, p 
0.001) (Figures 6C, D).
Each nN category was subdivided into pN1 and pN2
subgroups, and no significant difference in OS or DFS was
observed between the pN1 and pN2 subgroups (Figures
7A–F).
In a Cox regression analysis, the nN category was
identified as an independent prognostic factor for OS and
DFS (versus nN3, the hazard ratios [HR] of nN0, nN1, and
nN2 for OS were 0.123, 0.347, and 0.536 respectively, p 
0.001 for all of them; for DFS, the values were 0.088, 0.333,
and 0.543, respectively, p  0.001 for all of them) (Table 3).
The HR of pN1 versus pN2 was not significant for OS (HR
0.729, p  0.081) and was just narrowly significant for DFS
(HR 0.760, p 0.041) (Table 4). The HR of pN0 versus pN2
for OS and DFS were significant (0.222 and 0.173, respec-
tively, p  0.001 for both).
DISCUSSION
The TNM stage classification was developed to provide
high specificity for patients with a similar prognosis and
treatment options. As an essential component of this classi-
fication, nodal involvement was considered to be one of the
FIGURE 4. Disease-free survival
(DFS) and overall survival (OS) ac-
cording to pN stage classification
and nN category. A, DFS curves ac-
cording to pN stage classification.
Five-year DFS rate for pN0, pN1,
and pN2 was 83.2%, 37.3%, and
24.5%, respectively. B, OS curves
according to pN stage classification.
Five-year OS rate for pN0, pN1, and
pN2 was 89.2%, 55.4%, and
47.8%, respectively. C, DFS curves
according to nN category. Five-year
DFS rate for nN0, nN1, nN2, and
nN3 was 83.2%, 44.1%, 23.0%,
and 6.5%, respectively. D, OS
curves according to nN category.
Five-year OS rate for nN0, nN1,
nN2, and nN3 was 89.2%, 65.1%,
42.1% and 22.4%, respectively.
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most important prognostic factors that influenced the survival
of patients after surgery for primary NSCLC. The latest TNM
staging system for lung cancer included notable changes in
the T and M descriptors and the nodal map. However, the N
descriptor remained the same as that in the sixth edition and
depended solely on the anatomic extent of lymph node
involvement.1
The location-based pN classification has some unsatis-
factory aspects. The most important of these is the heteroge-
neity of pN1 and pN2 with regard to prognosis, which has
been well documented, and subclassifications have been pro-
posed.2–13 In addition, differences among surgeons in the
labeling of lymph node stations during surgery will always
occur despite the introduction of a new nodal map. For
FIGURE 5. Overall survival (OS)
curves according to nN category
across each pT stage. A, OS curves
according to nN category in pT1 pa-
tients. Five-year OS rate for nN0,
nN1, nN2, and nN3 was 94.1%,
81.5%, 65.5%, and 50.1%, respec-
tively. B, OS curves according to nN
category in pT2 patients. Five-year OS
rate for nN0, nN1, nN2, and nN3 was
82.6%, 55.0%, 31.9%, and 22.3%,
respectively. C, OS curves according
to nN category in pT3 patients. Five-
year OS rate for nN0, nN1, nN2, and
nN3 was 87.04%, 38.5%, 10.4% and
0%, respectively. D, OS curves ac-
cording to nN category in pT3 pa-
tients. Five-year OS rate for nN0,
nN1, nN2, and nN3 was 43.0%,
56.6%, 47.8%, and 0%, respectively.
FIGURE 6. Disease-free survival
(DFS) and overall survival (OS) ac-
cording to nN subgroup when pN1
and pN2 patients were subdivided
into different nN subgroups. A, DFS
curves according to nN subgroup in
pN1 patients. Five-year DFS rate for
nN1, nN2, and nN3 subgroup was
41.6%, 25.0%, and 40%, respec-
tively. B, OS curves according to nN
subgroup in pN1 patients. Five-year
OS rate for nN1, nN2, and nN3
subgroup was 61.5%, 35.6%, and
53.3%, respectively. C, DFS curves
according to nN subgroup in pN2
patients. Five-year DFS rate for nN1,
nN2, and nN3 subgroup was
48.0%, 23.0%, and 3.9%, respec-
tively. D, OS curves according to nN
subgroup in pN2 patients. Five-year
OS rate for nN1, nN2, and nN3
subgroup was 72.0%, 45.6%, and
19.4%, respectively.
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example, if a lymph node is located on the border between
stations 4 and 10 during an operation, the same lymph node
may be labeled as either N1 or N2 by different surgeons.
Therefore, it is necessary to develop a refined nodal category
that is simple and easy to use to provide more accurate
prognostic stratifications.
In the TNM classification for some other tumors, such
as gastric, breast, and colorectal cancer, the number of pos-
itive lymph nodes has been considered in the definition of pN
categories.14 In recent years, the association between the
number of metastatic lymph nodes and the prognosis in
resected NSCLC has also been explored. Lee et al.15 demon-
strated a stepwise deterioration with an increase in the num-
ber of positive nodes. Excellent agreement was observed
between the pN and nN categories. In another study by Fukui
et al.,9 the number category defined in their study was shown
to be an independent prognostic factor that could be used to
stratify pN2 patients into homogenous subgroups. However,
neither of these studies determined whether the pN stage
classification or the nN category is the better prognostic
factor. In this study, we retrospectively explored the associ-
ation between the number of metastatic lymph nodes and the
prognosis in 1659 resected NSCLC patients and compared
the results with the classic pN stage.
In our series, although there was a significant difference
in DFS between pN1 and pN2, the OS curves for the two
categories were close to each other, and no significant differ-
ence was observed (p  0.245). A multivariate analysis
demonstrated similar results. These results implied that the
pN classification had poor discriminative ability with regard
to the prognosis in patients with lymph node metastasis and
were very different from the report by Fukui et al.9 and other
prior reports.11,19 While the reason for this difference is
unclear, it is notable that the 5-year OS rate of pN2 patients
in our study was 47.8%, which was much higher than that in
prior reports9,11 and close to that for pN1. This result might be
due to the fact that all the pN2 patients who underwent
surgery in this study were mN2 disease (N2-positive based
FIGURE 7. Disease-free survival
(DFS) and overall survival (OS) ac-
cording to pN subgroup when nN1,
nN2, and nN3 patients were subdi-
vided into pN1 and pN2 subgroups.
A, DFS curves according to pN sub-
group in nN1 patients. Five-year
DFS rate for pN1 and pN2 sub-
group was 41.6% and 48.0%, re-
spectively. B, OS curves according
to pN subgroup in nN1 patients.
Five-year OS rate for pN1 and pN2
subgroup was 61.5% and 72.0%,
respectively. C, DFS curves accord-
ing to pN subgroup in nN2 pa-
tients. Five-year DFS rate for pN1
and pN2 subgroup was 25.5% and
23.0%, respectively. D, OS curves
according to pN subgroup in nN2
patients. Five-year OS rate for pN1
and pN2 subgroup was 35.6% and
45.6%, respectively. E, DFS curves
according to pN subgroup in nN3
patients. Five-year DFS rate for pN1
and pN2 subgroup was 40.0% and
3.9%, respectively. F, OS curves ac-
cording to pN subgroup in nN3 pa-
tients. Five-year OS rate for pN1
and pN2 subgroup was 53.3% and
19.4%, respectively.
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solely on a postoperative pathologic examination), and the
exclusion criteria of cN2 disease was much stricter than that
set by Fukui et al., who excluded only bulky N2 disease with
extranodal invasion,9 which resulted in a higher percentage
and lower 5-year survival of pN2 population in their series
than in ours (versus ours: 22% versus 14.6% and 40% versus
TABLE 3. Multivariate Analysis of OS and DFS Including nN Category
Variable
OS DFS
Hazard
Ratio 95% CI p
Hazard
Ratio 95% CI p
Gender 0.621 0.449–0.859 0.004 — — —
Age 1.014 0.998–1.029 0.083 1.013 1.002–1.024 0.025
Surgical procedure (reference: wedge
resection/segmentectomy)
Lobectomy — — — 0.530 0.320–0.877 0.013
Bilobectomy — — — 0.465 0.244–0.887 0.020
Pneumonectomy — — — 0.609 0.328–1.131 0.116
Surgical margin 1.838 1.251–2.699 0.002 1.585 1.153–2.179 0.005
Histological type (reference:
adenocarcinoma)
Squamous cell carcinoma 1.200 0.852–1.691 0.297 0.755 0.569–1.002 0.052
Large cell carcinoma 1.625 0.881–2.997 0.120 1.759 1.093–2.832 0.020
Adenosquamous carcinoma 3.386 1.616–7.097 0.001 2.528 1.271–5.029 0.008
pT stage (reference: pT1)
pT2 2.676 1.841–3.890 0.001 2.257 1.742–2.923 0.001
pT3 4.571 2.842–7.350 0.001 3.966 2.745–5.732 0.001
pT4 4.556 2.861–7.257 0.001 4.032 2.888–5.627 0.001
nN category (reference: nN3)
nN0 0.123 0.080–0.191 0.001 0.088 0.063–0.125 0.001
nN1 0.347 0.222–0.542 0.001 0.333 0.237–0.468 0.001
nN2 0.536 0.343–0.836 0.001 0.543 0.389–0.759 0.001
OS, overall survival; DFS, disease-free survival; nN, number of metastatic lymph nodes; CI, confidence interval.
TABLE 4. Multivariate Analysis of OS and DFS Including pN Stage
Variable
OS DFS
Hazard
Ratio 95% CI p
Hazard
Ratio 95% CI p
Gender 0.673 0.486–0.932 0.017 — — —
Age 1.013 0.998–1.029 0.092 1.012 1.001–1.024 0.030
Surgical procedure (reference: wedge
resection/segmentectomy)
Lobectomy — — — 0.548 0.331–0.905 0.019
Bilobectomy — — — 0.557 0.294–1.056 0.073
Pneumonectomy — — — 0.754 0.409–1.388 0.364
Surgical margin 2.141 1.470–3.118 0.001 1.858 1.363–2.533 0.001
Histological type (reference:
adenocarcinoma)
Squamous cell carcinoma 1.148 0.815–1.617 0.429 0.700 0.529–0.927 0.013
Large cell carcinoma 1.620 0.874–3.003 0.126 1.808 1.123–2.910 0.015
Adenosquamous carcinoma 3.609 1.725–7.547 0.001 2.498 1.259–4.954 0.009
pT stage (reference: pT1)
pT2 2.880 1.989–4.171 0.001 2.359 1.824–3.050 0.001
pT3 4.529 2.811–7.298 0.001 3.769 2.609–5.444 0.001
pT4 4.714 2.962–7.503 0.001 4.175 2.994–5.821 0.001
pN stage (reference: pN2)
pN0 0.222 0.156–0.315 0.001 0.173 0.133–0.226 0.001
pN1 0.729 0.512–1.040 0.081 0.760 0.583–0.989 0.041
OS, overall survival; DFS, disease-free survival; CI, confidence interval.
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47.8%, respectively). In addition, refinement of the preoper-
ative work-up to screen cN2 disease and distant metastasis
also contributed to the higher OS rate of pN2.
We defined four nN categories according to the number
of nodes with metastasis and examined the respective sur-
vival curves. All the patients were stratified into four prog-
nostically distinct groups by the nN classification. When we
tried to validate the results across each pT stage, a clear
tendency of deterioration of OS from nN0 to nN3 in the same
pT stage can be observed, and the curves were split in pT1
and pT2 stage. The results indicated that nN category was a
prognostic factor even in the same pT stage. In the higher pT
stage of pT3 and pT4, however, the curves were not apart
from each other. In addition to the small number of the cases,
the other reason may be that the prognosis of the higher pT
stage was always poor regardless of the number of metastatic
lymph nodes, so the prognostic effect of nN category was not
well demonstrated in these populations.
In a multivariate analysis, the nN category was shown
to be an independent prognostic factor for both OS and DFS.
Furthermore, the nN category could be used to subdivide pN1
and pN2 patients into two (nN1 and nN2) and three (nN1,
nN2 and nN3) prognostically distinct subgroups, respec-
tively. These results showed that the nN category has a
powerful discriminative ability with respect to the prognosis
and that the pN1 and pN2 categories are prognostically
heterogeneous. However, the survival of the nN3 subgroup in
pN1 patients was not significantly different from that of the
nN1 and nN2 subgroups. It seems that the nN classification
does not have as strong a discriminative ability in pN1 as in
pN2 patients. It is difficult to explain this finding; however, it
may be, in part, due to the small size of the nN3 subgroup
(n  7) in pN1 patients. Another possible explanation is that
lymph node fragments were removed. During the operation,
some of the N1 lymph nodes were most likely removed in
fragments instead of intact because of adhesion to the bron-
chus and lung tissues. Each fragment may have been counted
as a single node during the pathologic examination. Thus, the
true number of metastatic lymph nodes may have been
overestimated, and this would bias the results toward null. In
contrast, most of the mediastinal lymph nodes (N2) were
removed en bloc with the adjacent soft tissue, and fewer
fragments than N1 nodes were produced. All these factors
may have contributed to the observed results.
When we subdivided the nN category into pN1 and
pN2 subgroups, no significant survival difference was ob-
served between the two subgroups. This indicated that, for
metastasis in the same number of lymph nodes, the anatomic
location of the positive node (N1 or N2) is not important for
postoperative survival. We tend to agree with the opinion that
the overall disease burden, rather than the anatomic location
of lymph node involvement, has the most important influence
on prognosis.11 Based on the finding in this study that the pN2
stage was accompanied by more lymph node metastasis than
the pN1 stage, we postulate that even the slightly higher DFS
rate in pN1 than pN2 was attributed to the smaller number of
metastatic lymph nodes.
Despite the benefits of nN category for predicting sur-
vival, it also has some limitations. As we discussed above, some
lymph nodes were inevitably removed in fragments, especially
in the N1 region, which could lead to an overestimation of the
number of metastatic nodes. Such an overestimation would bias
the results of this study toward null, and the true association
between the nN category and survival may be stronger than what
we observed. However, when the nN category is used clinically
as a prognostic tool, the survival risk of patients may be over-
estimated because of the presence of nodal fragments. To avoid
the overestimation, the surgeon should remove the lymph nodes
en bloc with the adjacent soft tissue to avoid fragments. If the
fragment is inevitable, it is necessary for the operator to put the
fragments from one single lymph node into a same bottle and
label it definitely.
Second, a sufficient number of retrieved lymph nodes is
essential to evaluate the true number of metastatic nodes. In
gastric cancer, at least 15 removed lymph nodes are required
to assure the reliability of the pN classification.20 In lung
cancer, there have long been controversies regarding the
extent of lymphadenectomy.18,21–23 Some reports have sug-
gested that the optimal number of removed lymph nodes is 11
to 16 to accurately assess stage I lung cancer.24,25 In the study
by Lee et al.,15 the removal of 11 nodes was set as a threshold
for inclusion in their study. In our study, we did not set a
threshold. We performed selective lymph node dissection
based on the lobe-specific patterns of nodal metastasis for all
but the high-risk patients. We think that the number of
metastatic lymph nodes should be stable as long as less
dissection is based on the idea of the lobe-specific nodal
metastasis.16,17,21,22
Third, it is difficult to accurately assess the number of
metastatic lymph nodes both preoperatively and in nonsurgi-
cal patients by CT scan or other methods currently used.
Although PET scan can discriminate some metastatic lymph
nodes, this is not sufficient to determine the nN category.
Therefore, the nN category will contribute less to determine
the optimal treatment before surgery. New methods that are
capable of identifying each metastatic lymph node for non-
surgical patients will need to be developed.
Finally, the optimal category definition for the number
of metastatic lymph nodes needs to be further explored. In
this study and previous studies by Lee et al.15 and Fukui et
al.,9 four categories were defined, and the patients without
lymph node metastasis were grouped into a single category.
However, for patients with metastatic lymph nodes, the cat-
egories had different definitions. Both the other two studies
showed the prognostic significance of the number of meta-
static lymph nodes based on their category definitions. Be-
cause the data are from different institutes, it is difficult to
discuss which category definition is the best. Further studies
are needed.
In summary, our results demonstrated that the location-
based pN stage classification had a poor discriminative ability
with regard to the prognosis in resected NSCLC, and patients
in pN1 and pN2 are prognostically heterogeneous. Despite
the limitations, the nN category as defined in this study is a
better prognostic determinant than the location-based pN
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stage. The overall disease burden, rather than the anatomic
location of lymph node involvement, may have the most
important influence on the prognosis. Furthermore, the num-
ber of metastatic lymph nodes is a more objective measure
than their location, because errors could be made in deter-
mining the location of metastatic nodes. Therefore, we be-
lieve that the number of metastatic lymph nodes should be
considered for the nodal stage classification in the future.
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